Top Page
BioArctic AB Class B
(BIOA.B)
BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)
BioArctic AB Class B Business Overview & Revenue Model
BioArctic AB Class B Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.92B | 257.35M | 616.00M | 228.29M | 23.15M | 62.35M |
| Gross Profit | 1.86B | 230.37M | 526.37M | 153.97M | -31.92M | 12.11M |
| EBITDA | 1.21B | -165.13M | 295.29M | 4.03M | -126.42M | -74.58M |
| Net Income | 999.69M | -177.08M | 229.25M | -11.18M | -119.79M | -68.52M |
Balance Sheet | ||||||
| Total Assets | 2.60B | 1.11B | 1.19B | 858.31M | 897.73M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.88B | 778.92M | 1.11B | 805.39M | 848.40M | 999.94M |
| Total Debt | 46.56M | 54.23M | 4.98M | 10.04M | 15.88M | 20.77M |
| Total Liabilities | 631.81M | 216.74M | 139.50M | 72.06M | 109.05M | 143.01M |
| Stockholders Equity | 1.97B | 894.94M | 1.05B | 786.24M | 788.68M | 907.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.09B | -342.97M | 302.25M | -44.38M | -144.84M | -104.81M |
| Operating Cash Flow | 1.09B | -316.33M | 309.69M | -31.64M | -140.46M | -92.34M |
| Investing Cash Flow | -589.92M | 205.63M | -507.49M | -12.76M | -4.41M | -12.52M |
| Financing Cash Flow | 27.63M | 5.69M | 14.06M | -2.81M | -7.39M | -6.60M |
BioArctic AB Class B Technical Analysis
BioArctic AB Class B Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €25.79B | 25.75 | 68.77% | ― | 1046.53% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.18B | -6.73 | -36.52% | ― | 533.73% | 20.92% | |
47 Neutral | €1.04B | -3.56 | -35.03% | ― | ― | 25.14% | |
45 Neutral | €2.37B | ― | -71.87% | ― | -91.85% | -6.65% | |
41 Neutral | kr3.09B | -3.42 | ― | ― | -5.69% | 21.58% | |
31 Underperform | €815.45M | -4.15 | 81.19% | ― | ― | ― |
BioArctic AB Class B Corporate Events
BioArctic AB’s partner Eisai presented promising data at the CTAD 2025 conference indicating that continued treatment with lecanemab (Leqembi®) could delay the progression of Alzheimer’s disease by up to 8.3 years in certain patient groups. The findings suggest that early initiation of treatment may significantly slow disease progression, offering hope for improved patient outcomes. Additionally, the subcutaneous formulation of lecanemab, approved for use in the U.S. and under review in Japan, demonstrated bioequivalence to intravenous dosing, maintaining efficacy and safety while offering a more convenient administration option.
BioArctic AB has issued 4,000 Class B shares as part of its 2019/2028 stock option program, bringing the total number of shares to 88,641,485. This issuance reflects the company’s ongoing efforts to incentivize its workforce and align their interests with corporate growth, potentially impacting its market position and stakeholder value.
BioArctic AB and its partner Eisai have submitted a new drug application in Japan for a subcutaneous formulation of Leqembi, an anti-amyloid treatment for Alzheimer’s disease. This new formulation allows for at-home administration, potentially reducing healthcare resource demands and streamlining treatment pathways, marking a significant advancement in Alzheimer’s care.
Eisai, in partnership with BioArctic AB, has completed the rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for Alzheimer’s treatment. If approved, this would allow patients to administer the treatment at home, potentially reducing healthcare resource utilization and streamlining the Alzheimer’s treatment pathway.
BioArctic AB announced that its partner Eisai will present new data on their Alzheimer’s treatment, lecanemab, at the CTAD conference. The presentations will cover long-term treatment benefits, safety, and real-world clinical practice insights, potentially impacting the company’s market positioning and offering new options for Alzheimer’s treatment.
BioArctic AB’s partner Eisai has received approval from the UK’s Medicines and Healthcare products Regulatory Agency for the intravenous maintenance dosing of Leqembi, a treatment for early Alzheimer’s disease. This approval allows patients to transition to a less frequent dosing schedule, potentially improving treatment adherence and quality of life for those affected by Alzheimer’s. The approval is based on successful Phase 3 clinical trial results and strengthens BioArctic and Eisai’s position in the Alzheimer’s treatment market.
BioArctic AB reported its Q3 2025 interim results, highlighting a significant increase in net revenues driven by royalties from its Alzheimer’s treatment, Leqembi, and a new agreement with Novartis. Despite the revenue growth, the company faced a loss for the period, reflecting ongoing investments in research and development. Key achievements include regulatory approvals and launches of Leqembi in multiple countries, enhancing BioArctic’s market presence and potential future revenue streams.
BioArctic AB announced it will release its third quarter financial report for 2025 on November 13, followed by an audiocast presentation and Q&A session led by the CEO and CFO. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.
BioArctic AB reported a significant increase in royalties from the sales of Leqembi®, with third-quarter 2025 sales reaching 18 billion yen, resulting in a 68% increase in royalties compared to the previous year. This growth underscores the successful commercialization of Leqembi, a key product in BioArctic’s portfolio, and highlights the company’s strong position in the Alzheimer’s treatment market, with ongoing collaborations and clinical studies further supporting its industry standing.
Health Canada has authorized Leqembi (lecanemab) for treating early Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. This approval marks a significant milestone as Leqembi is the first treatment in Canada targeting the disease’s underlying cause, potentially impacting the Alzheimer’s treatment landscape and offering new hope to patients and caregivers.
BioArctic AB has announced the formation of its Nomination Committee, which includes representatives from its three largest shareholders: Demban AB, Ackelsta AB, and The Fourth Swedish National Fund. This committee, representing a significant portion of the company’s shares and votes, will prepare proposals for the 2026 Annual General Meeting, impacting the company’s governance and strategic direction.
BioArctic AB has announced the first treatment of a patient with Leqembi in Finland, marking a significant milestone in its efforts to address early Alzheimer’s disease in the Nordics. The approval and implementation of Leqembi, which targets amyloid-beta protofibrils and amyloid plaque, represent a strategic advancement for BioArctic as it seeks to expand its impact in the pharmaceutical industry and provide new treatment options for Alzheimer’s patients.
BioArctic AB’s partner Eisai announced that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer’s treatment, has been recognized by TIME as one of the best innovations of 2025 in the Medical and Healthcare category. This recognition highlights the innovation’s impact on Alzheimer’s treatment and strengthens BioArctic’s position in the biopharmaceutical industry, potentially enhancing its market presence and stakeholder confidence.
BioArctic AB’s partner, Eisai, has launched Leqembi Iqlik, a subcutaneous injection for Alzheimer’s maintenance treatment in the U.S., offering a convenient at-home option for patients with early-stage Alzheimer’s. This development is expected to streamline treatment pathways, reduce healthcare resource demands, and enhance patient convenience, potentially strengthening BioArctic’s market position in Alzheimer’s therapies.
BioArctic AB’s partner Eisai announced that Leqembi® (lecanemab) has been approved for once every four weeks intravenous maintenance treatment for early Alzheimer’s disease by China’s National Medical Products Administration. This approval marks a significant advancement in Alzheimer’s treatment, as Leqembi is the only approved therapy targeting both amyloid plaque and protofibrils, potentially impacting the disease’s progression. The approval strengthens BioArctic’s market position and offers new opportunities for commercialization in China, benefiting stakeholders involved in Alzheimer’s disease treatment.
BioArctic AB announced that the Therapeutic Goods Administration (TGA) of Australia has approved Leqembi® for treating early Alzheimer’s disease in specific patient groups. This approval marks a significant milestone following a review process initiated by Eisai, BioArctic’s partner, after an initial rejection. The approval strengthens BioArctic’s and Eisai’s position in the Alzheimer’s treatment market, allowing them to expand their commercialization efforts, particularly in the Nordic region.
Gunilla Osswald, CEO of BioArctic AB, has been named Uppsala University’s Alumnus of the Year 2025, acknowledging her visionary leadership and contributions to science and technology. This recognition highlights her role in developing lecanemab, a groundbreaking Alzheimer’s treatment, and underscores her influence as a role model, particularly for women in STEM fields, reinforcing BioArctic’s position as a leader in neurodegenerative disease research.